Prostate Cancer International is
for 2011 by Great NonProfits
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The "New" Prostate Cancer InfoLink is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Perspective Confidentiality Disclosure Reliability Courtesy
Early data have suggested that a modified vaccinia Ankara (MVA) virus that expresses a tumor-associated glycoprotein called 5T4 may have activity in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) — among other forms of cancer. We will refer to this agent as MVA-5T4; the brand name is TroVax®.
Filed under: Drugs in development | Tagged: castration-resistant, mCRPC, metastatic, MVA-5T4, TroVax | 3 Comments »
According to media information from Active Biotech this morning, the company has initiated an early stage, combination therapy trial (the so-called CATCH trial) of their investigational agent tasquinimod + cabazitaxel (Jevtana®) for the treatment of men with heavily pre-treated, metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cabazitaxel, castration-resistant, Jevtana, mCRPC, metastatic, taquinimod | Leave a Comment »
In 2001, when he was just 49 years old, Ward “Trip” Casscells experienced lower back pain that became progressively worse. Then, he felt a lump in his abdominal area. He had an aggressive, metastatic prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: metastatic, remission, survival | 4 Comments »
According to a joint media release from Medivation and Astellas Pharma earlier today, the full results of the Phase III AFFIRM trial — of MDV3100 in men with metastatic castration-resistant prostate cancer (mCRPC) who have received docetaxel chemotherapy — will be presented at the ASCO Genitourinary Oncology meeting on February 2, 2012.
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, mCRPC, MDV3100, metastatic | Leave a Comment »
Additional data about the effectiveness and safety of cabozantinib were reported over the past weekend at a meeting in San Francisco.
Filed under: Drugs in development, Management, Treatment, Uncategorized | Tagged: cabozantinib, castration-resistant, mCRPC, metastatic, XL184 | Leave a Comment »
A new article by Antonarakis and Armstrong in full text on the Medscape web site reviews available information on a wide range of currently investigational agents for the treatment of metastatic, castration-resistant prostate cancer (mCRPC), including
Filed under: Drugs in development, Management, Treatment | Tagged: advanced, castration-resistant, investigational, mCRPC, metastatic | 3 Comments »
In May 2010 we reported that a product called eribulin mesylate had been tested (in the USA) in a Phase II clinical trial for its activity in metastatic, castration-resistant prostate cancer (mCRPC) — and that the results were not particularly promising.
Filed under: Drugs in development, Management, Treatment | Tagged: castration-resistant, eribulin, mCRPC, metastatic | 3 Comments »
We apparently managed to overlook a series of three review and commentary articles published in Oncology in May this year that dealt with the evolving options that have already — or will soon — come available for the treatment of castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, CRPC, hormone-resistant, mCRPC, metastatic | 2 Comments »
According to a retrospective analysis of data from a randomized, double-blind, Phase III clinical trial, abiraterone acetate (Zytiga™) can significantly lower levels of fatigue in men with metastatic, castration-resistant prostate cancer (as well extending survival).
Filed under: Living with Prostate Cancer, Treatment | Tagged: abiraterone, castration-resistant, fatigue, metastatic | 2 Comments »
Oncothyreon, Inc. has announced initiation of a Phase II clinical trial of the company’s investigational agent PX-866 in the treatment of men with chemotherapy-naïve, recurrent or metastatic, castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development, Management | Tagged: castration-resistant, inhibitor, kinase, metastatic, Oncothyreon, PX-866 | Leave a Comment »
Exelexis has issued a media release stating that “the pre-specified number of progression-free survival (PFS) events required for un-blinding of the data for the ongoing Phase III pivotal trial of cabozantinib in patients with medullary thyroid cancer (MTC), known as the EXAM trial, has been reached.”
Filed under: Drugs in development, Management, Treatment | Tagged: cabozantinib, castration-resistant, metastatic | 5 Comments »
According to a media release issued by Bayer HealthCare, the U. S. Food & Drug Administration (FDA) has given the green light to “fast track” review of the company’s new drug application (NDA) for Alpharadin™ (radium-223 chloride) as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Drugs in development, Management, Treatment | Tagged: Alpharadin, castration-resistant, mCRPC, metastatic, radium-223 | 3 Comments »
We have reported on a number of attempts to use tyrosine kinase inhibitors (TKIs) — alone or in combination with chemotherapy — in the treatment of men with castration-resistant prostate cancer (CRPC). Limited activity or efficacy has been reported to date.
Filed under: Drugs in development, Management, Treatment | Tagged: bicalutamide, castration-resistant, CRPC, metastatic, sorefanib, TKI, tyrosine kinase inhibitor | Leave a Comment »
The levels of circulating tumor cells (CTCs) — as evaluated using Cellsearch technology — is becoming accepted as a prognostic marker for disease progression among men with metastatic castration-resistant prostate cancer (mCRPC), and may even be accepted soon as a surrogate marker for prostate cancer-specific mortality in clinical trials of new agents.
Filed under: Living with Prostate Cancer, Management | Tagged: circulating tumor cells, CTC, hormone, hormone-sensitive, metastatic, therapy | 2 Comments »
The investigational radioisotope radium-233 chloride (Alpharadin) has shown a small but clinically significant overall survival benefit in the treatment of men with symptomatic, metastatic, castration-resistant prostate cancer (mCRPC).
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: Alpharadin, castration-resistant, metastatic, radium-233 chloride, survival | 3 Comments »
Blog at WordPress.com. Theme: Digg 3 Column by WP Designer.
Search for new and
ongoing trials on the
CTAG PCa web site